Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4503-4506

  Goyeneche Patino, Diego A ^a   Valderrama, Liliana ^a   Walker, John ^a   Saravia, Nancy G ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; BUTHIONINE SULFOXIMINE; EFLORNITHINE; MEGLUMINE ANTIMONATE; TRYPANOTHIONE;

AMASTIGOTE; ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN; INFECTION RESISTANCE; LEISHMANIA PANAMENSIS; LEISHMANIASIS; NONHUMAN; PARASITE ISOLATION; PRIORITY JOURNAL; PROMASTIGOTE; TREATMENT FAILURE;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; BUTHIONINE SULFOXIMINE; DRUG RESISTANCE; GLUTATHIONE; HUMANS; LEISHMANIA; LEISHMANIASIS; PARASITIC SENSITIVITY TESTS; SPERMIDINE;

EID: 57049136229     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01075-08     Document Type: Article

References (30)

1. Abdo, M. G., W. M. Elamin, E. A. Khalil, and M. M. Mukhtar. 2003. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation. East Mediterr. Health J. 9:837-843.
2. Ariyanayagam, M. R., and A. H. Fairlamb. 2001. Ovothiol and trypanothione as antioxidants in trypanosomatids. Mol. Biochem. Parasitol. 115:189-198.
3. Basselin, M., G. H. Coombs, and M. P. Barrett. 2000. Putrescine and spermidine transport in Leishmania. Mol. Biochem. Parasitol. 109:37-46.
4. Bodley, A. L., M. W. McGarry, and T. A. Shapiro. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J. Infect. Dis. 172: 1157-1159.
5. Bosque, F., G. Milon, L. Valderrama, and N. G. Saravia. 1998. Permissiveness of human monocytes and monocyte-derived macrophages to infection by promastigotes of Leishmania (Viannia) panamensis. J. Parasitol. 84:1250-1256.
6. Bras, A. P., J. Janne, C. W. Porter, and D. S. Sitar. 2001. Spermidine/spermine N(1)-acetyltransferase catalyzes amantadine acetylation. Drug Metab. Dispos. 29:676-680.
7. Brochu, C., J. Wang, G. Roy, N. Messier, X. Y. Wang, N. G. Saravia, and M. Ouellette. 2003. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob. Agents Chemother. 47:3073-3079.
8. Chulay, J. D., L. Fleckenstein, and D. H. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:69-72.
9. Cruz, A., P. M. Rainey, B. L. Herwaldt, G. Stagni, R. Palacios, R. Trujillo, and N. G. Saravia. 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J. Infect. Dis. 195:602-608.
10. Danfour, M., C. J. Schorah, and S. W. Evans. 1999. Changes in sensitivity of a human myeloid cell line (U937) to metal toxicity after glutathione depletion. Immunopharmacol. Immunotoxicol. 21:277-293.
11. Decuypere, S., S. Rijal, V. Yardley, S. De Doncker, T. Laurent, B. Khanal, F. Chappuis, and J. C. Dujardin. 2005. Gene expression analysis of the mechanism of natural SbV resistance in Leishmania donovani isolates from Nepal. Antimicrob. Agents Chemother. 49:4616-4621.
12. Denton, H., J. C. McGregor, and G. H. Coombs. 2004. Reduction of antileishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J. 381:405-412.
13. El Fadili, K., N. Messier, P. Leprohon, G. Roy, C. Guimond, N. Trudel, N. G. Saravia, B. Papadopoulou, D. Legare, and M. Ouellette. 2005. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob. Agents Chemother. 49:1988-1993.
14. Fairlamb, A. H., and A. Cerami. 1992. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol. 46:695-729.
15. Gourbal, B., N. Sonuc, H. Bhattacharjee, D. Legare, S. Sundar, M. Ouellette, B. P. Rosen, and R. Mukhopadhyay. 2004. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 279: 31010-31017.
16. Grondin, K., A. Haimeur, R. Mukhopadhyay, B. P. Rosen, and M. Ouellette. 1997. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 16:3057-3065.
17. Haimeur, A., C. Guimond, S. Pilote, R. Mukhopadhyay, B. P. Rosen, R. Poulin, and M. Ouellette. 1999. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol. Microbiol. 34:726-735.
18. Legare, D., D. Richard, R. Mukhopadhyay, Y. D. Stierhof, B. P. Rosen, A. Haimeur, B. Papadopoulou, and M. Ouellette. 2001. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 276:26301-26307.
19. Lira, R., S. Sundar, A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
20. Mittal, M. K., S. Rai, Ashutosh, Ravinder, S. Gupta, S. Sundar, and N. Goyal. 2007. Characterization of natural antimony resistance in Leishmania donovani isolates. Am. J. Trop. Med. Hyg. 76:681-688.
21. Mukhopadhyay, R., S. Dey, N. Xu, D. Gage, J. Lightbody, M. Ouellette, and B. P. Rosen. 1996. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. USA 93:10383-10387.
22. Muller, S., G. H. Coombs, and R. D. Walter. 2001. Targeting polyamines of parasitic protozoa in chemotherapy. Trends Parasitol. 17:242-249.
23. Palacios, R., L. E. Osorio, L. F. Grajalew, and M. T. Ochoa. 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg. 64:187-193.
24. Rijal, S., V. Yardley, F. Chappuis, S. Decuypere, B. Khanal, R. Singh, M. Boelaert, S. De Doncker, S. Croft, and J. C. Dujardin. 2007. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect. 9:529-535.
25. Roberts, W. L., J. D. Berman, and P. M. Rainey. 1995. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39:1234-1239.
26. Rojas, R., L. Valderrama, M. Valderrama, M. X. Varona, M. Ouellette, and N. G. Saravia. 2006. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 193:1375-1383.
27. Sereno, D., M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 42:3097-3102.
28. Shaked-Mishan, P., N. Ulrich, M. Ephros, and D. Zilberstein. 2001. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276:3971-3976.
29. Sundar, S., K. Pai, R. Kumar, K. Pathak-Tripathi, A. A. Gam, M. Ray, and R. T. Kenney. 2001. Resistance to treatment in kala-azar: speciation of isolates from northeast India. Am. J. Trop. Med. Hyg. 65:193-196.
30. Zhou, Y., N. Messier, M. Ouellette, B. P. Rosen, and R. Mukhopadhyay. 2004. Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J. Biol. Chem. 279:37445-37451.